Breaking News Instant updates and real-time market news.

VRX

Ticker changed BHC

$15.37

0.235 (1.55%)

08:22
08/08/17
08/08
08:22
08/08/17
08:22

Valeant CFO says Salix business had 'very strong quarter'

Herendeen said Salix "had a very strong quarter, posting organic growth of 16%. We enjoyed improved net pricing in the Salix business as result of modest price increases across the GI portfolio as well as favorable gross-to-net items compared with the prior year quarter. While the improved net pricing is awesome, I just caution that part of that improvement is less durable than the rest. Also encouraging, Salix volume was up over the prior year quarter by some of 350 basis points, mainly driven by increased demand from XIFAXAN. We made considerable investments in the new Primary Care sales team, and we're starting to see measurable progress growing XIFAXAN prescriptions for IBS-D." In Q2, total prescriptions for XIFAXAN were up 2% while extended units, which means the total prescriptions multiplied by the bills for Rx, were up 4% compared with Q2 last year, he noted. Valeant CFO Paul Herendeen is speaking on the company's Q2 earnings call.

  • 08

    Aug

  • 24

    Aug

VRX Ticker changed BHC
$15.37

0.235 (1.55%)

07/17/17
WELS
07/17/17
NO CHANGE
WELS
Underperform
Wells says Valeant selling Obagi for less than half of price paid in 2013
After Valeant announced it has agreed to sell its Obagi Medical Products business for $190M in cash, Wells Fargo analyst David Maris noted that this sale price is less than half of the $437M that the company paid to acquire Obagi in April 2013. While Valeant continues to make progress toward its asset sales and debt reduction targets, Maris does not believe that its recent divestitures have had a significant deleveraging impact. He keeps an Underperform rating on Valeant shares.
07/27/17
WELS
07/27/17
NO CHANGE
WELS
Underperform
Doctors not optimistic about Valeant's Siliq, says Wells Fargo
Wells Fargo analyst David Maris says the dozens of doctors he spoke to about Valeant Pharmaceuticals' Siliq are not optimistic. Over 50% of the physicians surveyed said they would use Siliq only as a fourth line therapy or later, Maris tells investors in a research note after Valeant announced the launch of the moderate-to-severe plaque psoriasis treatment. The analyst disagrees with Valeant management's claims that Siliq has "very large peak sales potential." The injection carries a warning about risk of suicide and Valeant will be competing against a large number of peers with greater resources, Maris argues. The analyst has an Underperform rating on Valeant shares, which are down 18c to $17.59 in midday trading.
07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
08/04/17
WELS
08/04/17
NO CHANGE
WELS
Underperform
Valeant's Isuprel to face generic from Nexus, says Wells Fargo
Wells Fargo analyst David Maris noted that the FDA is reporting, and Nexus Pharmaceuticals has confirmed to him, that the company received approval for a generic version of Valeant's Isuprel. Nexus expects to "command the lion's share" of the U.S. market for the drug, as its version is made in the U.S. and has longer stability than Valeant's version, Maris tells investors. The analyst, who notes that Valeant previously indicated it anticipated that Isuprel would lose exclusivity in Q4, keeps an Underperform rating on the stock.

TODAY'S FREE FLY STORIES

KRNY

Kearny Financial

$13.75

0.25 (1.85%)

18:02
09/19/18
09/19
18:02
09/19/18
18:02
Hot Stocks
Kearny Financial declares special cash dividend of 16c per share »

Kearny Financial has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVA

Avista

$51.50

0.01 (0.02%)

18:00
09/19/18
09/19
18:00
09/19/18
18:00
Hot Stocks
Avista, Hydro One extend merger end date »

Hydro One Limited and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,926.27

-14.93 (-0.77%)

17:57
09/19/18
09/19
17:57
09/19/18
17:57
Periodicals
Amazon leaks new Alexa smart plug and a subwoofer, Verge says »

According to the Verge,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$163.06

2.75 (1.72%)

17:45
09/19/18
09/19
17:45
09/19/18
17:45
Periodicals
Facebook sets up 'War Room' for safeguarding elections, NY Times says »

After Facebook gained…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

RRTS

Roadrunner

$1.16

-0.065 (-5.33%)

17:45
09/19/18
09/19
17:45
09/19/18
17:45
Syndicate
Roadrunner files S-1 for rights offering to existing holders »

Roadrunner announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$26.45

0.3 (1.15%)

17:35
09/19/18
09/19
17:35
09/19/18
17:35
Hot Stocks
Associated Banc-Corp announces $200M share repurchase program »

Associated's Board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLIN

Bridgeline Digital

$1.02

-0.01 (-0.98%)

17:32
09/19/18
09/19
17:32
09/19/18
17:32
Syndicate
Breaking Syndicate news story on Bridgeline Digital »

Bridgeline Digital files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGD

New Gold

$1.10

0.03 (2.80%)

17:29
09/19/18
09/19
17:29
09/19/18
17:29
Hot Stocks
New Gold sells Mesquite Mine to Eqiunox Gold for $158M »

New Gold has entered into…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$291.22

0.26 (0.09%)

17:23
09/19/18
09/19
17:23
09/19/18
17:23
Periodicals
Trudeau wants to see more U.S. flexibility around NAFTA, Reuters says »

Canadian prime minister…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$291.22

0.26 (0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$339.26

-3.94 (-1.15%)

17:18
09/19/18
09/19
17:18
09/19/18
17:18
Hot Stocks
Lockheed Martin awarded $132.3M U.S. Navy contract modification »

Lockheed Martin Rotary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHT

Red Hat

$143.38

0.59 (0.41%)

17:17
09/19/18
09/19
17:17
09/19/18
17:17
Hot Stocks
Breaking Hot Stocks news story on Red Hat »

Red Hat CFO sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ELAN

Elanco

$0.00

(0.00%)

17:14
09/19/18
09/19
17:14
09/19/18
17:14
Syndicate
Elanco 62.9M share IPO priced at $24.00 »

The IPO priced above its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MAMS

MAM Software

$7.67

0.02 (0.26%)

17:10
09/19/18
09/19
17:10
09/19/18
17:10
Hot Stocks
MAM Software announces $2M share repurchase program »

MAM Software Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

17:08
09/19/18
09/19
17:08
09/19/18
17:08
Hot Stocks
Coinbase names Brian Brooks chief legal officer »

Coinbase said in a blog…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

FNMA

Fannie Mae

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHT

Red Hat

$143.38

0.59 (0.41%)

17:07
09/19/18
09/19
17:07
09/19/18
17:07
Hot Stocks
Breaking Hot Stocks news story on Red Hat »

Red Hat CEO says he…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

RHT

Red Hat

$143.38

0.59 (0.41%)

17:06
09/19/18
09/19
17:06
09/19/18
17:06
Hot Stocks
Breaking Hot Stocks news story on Red Hat »

Red Hat says 24 of its 25…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

RHT

Red Hat

$143.38

0.59 (0.41%)

17:05
09/19/18
09/19
17:05
09/19/18
17:05
Hot Stocks
Red Hat Q2 backlog was up 20% on the year »

Deals over $1M were up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

RRTS

Roadrunner

$1.16

-0.065 (-5.33%)

17:01
09/19/18
09/19
17:01
09/19/18
17:01
Syndicate
Breaking Syndicate news story on Roadrunner »

Roadrunner files $450M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYAM

Rayonier Advanced Materials

$21.39

0.165 (0.78%)

16:58
09/19/18
09/19
16:58
09/19/18
16:58
Hot Stocks
Rayonier Advanced Materials sells resins business to LRBG Chemicals for $16.5M »

Rayonier Advanced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

UNIT

Uniti Group

$20.82

-0.1 (-0.48%)

16:57
09/19/18
09/19
16:57
09/19/18
16:57
Hot Stocks
Uniti Group completes sale-leaseback and fiber acquisition with U.S.TelePacific »

Uniti Group announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBTYA

Liberty Global

$28.59

0.32 (1.13%)

, LBTYK

Liberty Global

$27.62

0.35 (1.28%)

16:57
09/19/18
09/19
16:57
09/19/18
16:57
Conference/Events
Liberty Global management to meet with Evercore ISI »

Group Luncheon Meeting to…

LBTYA

Liberty Global

$28.59

0.32 (1.13%)

LBTYK

Liberty Global

$27.62

0.35 (1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

  • 28

    Sep

HEAR

Turtle Beach

$19.19

1.44 (8.11%)

16:54
09/19/18
09/19
16:54
09/19/18
16:54
Hot Stocks
Breaking Hot Stocks news story on Turtle Beach »

Vinik Family Investments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRC

Nac Re

$38.10

-1.25 (-3.18%)

16:54
09/19/18
09/19
16:54
09/19/18
16:54
Hot Stocks
National Research director Donald Berwick sells 17K shares of company stock »

National Research…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGA

Magna

$54.44

0.805 (1.50%)

16:53
09/19/18
09/19
16:53
09/19/18
16:53
Conference/Events
Magna management to meet with Evercore ISI »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

NVCR

Novocure

$52.05

3.05 (6.22%)

16:51
09/19/18
09/19
16:51
09/19/18
16:51
Conference/Events
Novocure management to meet with Evercore ISI »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.